Owing to the institution of annual low-dose CT for lung cancer screening in the USA, the presumed increase in detection of early stage lung cancers elicits many questions about so-called 'grey areas' of the management of this disease that have been inadequately addressed to date. Herein, important and potentially difficult ambiguous cases that oncologists might come across are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jensen, T. S., Chin, J., Ashby, L., Hermansen, J. & Hutter, J. D. Final National Coverage Determination on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). CMS.gov: Centers for Medicare & Medicaid Services [online], (2015).
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Grills, I. S. et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J. Clin. Oncol. 28, 928–935 (2010).
Lagerwaard, F. J. et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 348–353 (2012).
Palma, D. et al. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother. Oncol. 101, 240–244 (2011).
Timmerman, R. et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J. Clin. Oncol. 24, 4833–4839 (2006).
Onishi, H. et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int. J. Radiat. Oncol. Biol. Phys. 81, 1352–1358 (2011).
Nagata, Y. et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int. J. Radiat. Oncol. Biol. Phys. 78, S27–S28 (2010).
Timmerman, R. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303, 1070–1076 (2010).
Marwaha, G., Stephans, K. L., Woody, N. M., Reddy, C. A. & Videtic, G. M. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size. J. Thorac. Oncol. 9, 1693–1697 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Verma, V. Implementing lung-cancer screening—oncological 'grey areas'. Nat Rev Clin Oncol 12, 256–257 (2015). https://doi.org/10.1038/nrclinonc.2015.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.65
